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Abstract
Background: Only a few studies have addressed the molecular pathways specifically involved in carcinogenesis of
the distal colon and rectum. We aimed to identify potential differences among genetic alterations in distal colon
and rectal carcinomas as compared to cancers arising elsewhere in the large bowel.
Methods: Constitutional and tumor DNA from a test series of 37 patients with rectal and 25 patients with sigmoid
carcinomas, previously analyzed for microsatellite instability (MSI), was studied for BAX, IGF2R, TGFBR2, MSH3, and
MSH6 microsatellite sequence alterations, BRAF and KRAS mutations, and MLH1 promoter methylation. The findings
were then compared with those of an independent validation series consisting of 36 MSI-H carcinomas with origin
from each of the large bowel regions. Immunohistochemical and germline mutation analyses of the mismatch
repair system were performed when appropriate.
Results: In the test series, IGFR2 and BAX mutations were present in one and two out of the six distal MSI-H
carcinomas, respectively, and no mutations were detected in TGFBR2, MSH3, and MSH6. We confirmed these
findings in the validation series, with TGFBR2 and MSH3 microsatellite mutations occurring less frequently in MSI-H
rectal and sigmoid carcinomas than in MSI-H colon carcinomas elsewhere (P = 0.00005 and P = 0.0000005,
respectively, when considering all MSI-carcinomas of both series). No MLH1 promoter methylation was observed in
the MSI-H rectal and sigmoid carcinomas of both series, as compared to 53% found in MSI-H carcinomas from
other locations (P = 0.004). KRAS and BRAF mutational frequencies were 19% and 43% in proximal carcinomas and
25% and 17% in rectal/sigmoid carcinomas, respectively.
Conclusion: The mechanism and the pattern of genetic changes driving MSI-H carcinogenesis in distal colon and
rectum appears to differ from that occurring elsewhere in the colon and further investigation is warranted both in
patients with sporadic or hereditary disease.
Background
Colorectal cancer is the third most common neoplasia
in the Western world, preceded only by lung cancer in
male and breast cancer in female [1]. Approximately 25
to 35% of colorectal cancers are located in the rectum.
Multiple differences between cancer of the right and left
colon and rectum with regard to epidemiological, clini-
cal behavior, pathological and molecular features suggest
that the mechanisms of sporadic colorectal carcinogen-
esis may differ according to tumor location [2,3]. A pos-
sible explanation for this could be the different
embryological origin of the large intestine, as the
ascending and two thirds of the transverse colon origi-
nate from the midgut and the last third of transverse,
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Although few studies have separately analyzed rectal
cancer they indicate that approximately 80 to 98% of
these cancers arise through the chromosomal instability
pathway (CIN), presenting high mutational frequency in
APC, TP53, and KRAS in addition to numerous chromo-
some changes [2,3,5]. Nonetheless, a few rectal cancers
can develop through the microsatellite instability (MSI)
pathway [2,5].
MSI is a widespread instability in coding and noncod-
ing microsatellite sequences, due to mismatch repair
(MMR) deficiency [6]. Through the MSI pathway, color-
ectal cancer progression is accelerated through accumu-
lation of mutations in coding repetitive sequences of
target genes with growth-related functions. However,
most of the microsatellite mutations observed in MMR-
deficient cells are bystander events that do not play a
causal role in carcinogenesis. Criteria to clarify what
constitutes a true MSI target gene have been proposed,
although most studies have relied on mutation fre-
quency data and on functional studies [7,8]. In colorec-
tal cancer, mutations have been found in a number of
genes with key cellular roles, such as growth factor
receptors (TGFBR2 and IGF2R), genes involved in apop-
tosis (BAX), as well as genes relevant for DNA repair
(MSH3, MSH6) [6,9]. MSI frequency reported in rectal
cancer is < 10%, but it is unknown whether or not the
same target genes are involved [10].
KRAS and BRAF gene mutations are associated with
colorectal development through both CIN and MSI path-
ways. These genes are members of the mitogen activated
protein kinase (MAPK) pathway, which regulates cell
proliferation, differentiation, senescence and apoptosis
[11]. KRAS mutations are present in 30 to 50% of color-
ectal carcinomas, occurring mainly in codons 12 and 13
[12-14]. BRAF mutations are present in 3.7 to 21% of col-
orectal carcinomas, mainly in codon 600 [13,15-17]. Only
a small number of studies have specifically addressed the
mutational frequency of KRAS and BRAF in rectal carci-
nomas, reporting a mutational frequency of 21 to 46% for
KRAS and about 4% for BRAF [12,13].
We have previously reported the frequency of nuclear
(MSI) and mitochondrial instability in a series of rectal
and sigmoid carcinomas [18]. In this study, we aimed to
further contribute to the understanding of the pathoge-
netic mechanisms operating in distal colon and rectal
cancers compared to those arising elsewhere in the large
bowel.
Methods
Patient characteristics and DNA extraction
Our test series consisted of 37 rectal and 25 sigmoid can-
cer patients treated by surgical resection at the Portuguese
Oncology Institute-Porto, which have previously been
analyzed for nuclear (MSI) and mitochondrial instability
(one rectal cancer was excluded from the initial series
because the patient had received neoadjuvant treatment)
[18]. As described, all tumor samples were paraffin
embedded and reviewed by a pathologist (LA) and periph-
eral blood or normal mucosa was also collected from the
same patients. The minimal percentage of tumor cells in
the tissue sections was 50%. Clinical data were obtained
from hospital records and tumor staging was performed
using the American Joint Committee on Cancer (AJCC)
criteria. Family history was assessed from hospital records
and none of the patients presented a family or personal
history indicative of familial adenomatous polyposis (FAP),
MYH-associated polyposis (MAP) or hereditary non-poly-
posis colorectal cancer (HNPCC). This study was
approved by the Institutional Review Board of the Portu-
guese Oncology Institute-Porto. DNA was isolated from
paraffin-embedded tumor and normal mucosa as
described by Lungu et al [19] and from peripheral blood
using the salt-chloroform extraction method [20].
The data from an independent series of 36 MSI-H
carcinomas was included for validation. These carcino-
mas were fresh frozen from patients treated in Norway
and included eight caecum, eight ascending colon, six
right flexure colon, four left colon (including three flex-
ure/transverse and one descending colon), three sigmoid
and seven rectal carcinomas [21]. This validation series
included only sporadic tumors as determined by written
questionnaires [21].
Microsatellite instability and target gene analyses
MSI evaluation of the test series has been previously
published by our group and was performed using the
Bethesda panel of markers (BAT25, BAT26, D2S123,
D5S346 and D17S250) and the 1997 National Cancer
Institute guidelines [18]. MSI evaluation of the valida-
tion series was performed as for the test series [21].
Microsatellite sequences of the potential target genes
TGFBR2 (A10),B A X(G8),I G F 2 R(G8), MSH3 (A8) and
MSH6 (C8) were analyzed by PCR and fragment analy-
sis. PCR was carried out as previously described using
fluorescence-labeled primers [22,23]. Fragments were
analyzed for length variations on an ABI Prism 310
DNA sequencer (the test series) (Applied Biosystems,
Foster City, CA, USA) and a 3730 DNA Analyzer (the
validation series) (Applied Biosystems) and allele sizes
were determined using Genemapper software (version
3.7, Applied Biosystems). The results were indepen-
dently scored by two observers and a second round of
analyses confirmed the results.
BRAF exon 15 and KRAS exon 2 mutation screening
BRAF exon 15 and KRAS exon 2 (coding exon 1) were
analyzed for mutations by direct sequencing on an ABI
Pinheiro et al. BMC Cancer 2010, 10:587
http://www.biomedcentral.com/1471-2407/10/587
Page 2 of 9PRISM 310 automatic sequencer using Big Dye Termi-
nator V1.1 Chemistry (Applied Biosystems), according
to the manufacturer’ s recommendations and as pre-
viously described [15]. Data analysis was performed by
Sequencing Analysis software (version 5.2, Applied Bio-
systems). In the validation MSI-H carcinomas series,
BRAF exon 15 and KRAS exon 2 mutation analyses had
previously been performed in 27 and 36 of the 36 cases,
respectively, as described by Ahlquist et al [24].
MLH1 gene promoter methylation analysis
The methylation status of the MLH1 gene promoter was
determined in the six MSI-H carcinomas from the test
series and in the respective normal samples by two dif-
ferent techniques: methylation-specific multiplex liga-
tion-dependent probe amplification (MS-MLPA) and
methylation-specific PCR (MSP). MS-MLPA was per-
formed according to the SALSA MS-MLPA ME001B
Tumor suppressor-1 Kit (MRC-Holland) instructions. In
order to confirm the results obtained by MS-MLPA, we
performed MSP after chemical treatment of two μgo f
genomic DNA with sodium bisulfite, as previously
described [25]. One set of methylation-dependent and
unmethylation-dependent primers for the MLH1 gene
promoter region covering the 1686-L1266 probe region
of the TS1 MS-MLPA kit were designed using Methy-
lExpress software (1.0 version, Applied Biosystems). Pri-
mer sequences for the unmethylated reaction were 5’
-GGTTTTTTTGGTGTTAAAATGTT-3’ (forward) and
5’ -CTTAAATAAACCCAACTCAACTC-3’ (reverse)
and for the methylated reaction were 5’ -TTTTTTG
GCGTTAAAATGTC-3 (forward) and 5’ - AAATAAA
CCCGACTCGACTC-3’ (reverse).
In the validation MSI-H carcinomas series, MLH1
promoter methylation was analyzed in 25 of the 36
cases (three caecum, eight ascending colon, five right
flexure, three left colon, two sigmoid and four rectal
carcinomas). MLH1 promoter methylation of this series
has previously been performed by MSP as described by
Lind et al (2004) [26].
MMR immunohistochemical analysis
Assessment of MLH1, MSH2, and MSH6 immunoex-
pression was evaluated in the six MSI-H carcinomas of
the test series, with PMS2 being evaluated in the four
MSI-H carcinomas with normal expression of the other
three MMR proteins. Four μm sections were cut and
placed in silanyzed slides. Immunostaining was per-
formed using an avidin-biotin complex peroxidase
method (Elite PK-6200, Vector, Burlingame, CA, USA).
Briefly, after dewaxing the sections, endogenous peroxi-
dase activity was inhibited with freshly prepared 0.5%
hydrogen peroxide in distilled water for 20 min. Antigen
retrieval was performed with EDTA buffer, pH8, for 40
minutes. Incubation with primary antibodies for MLH1
(Clone G168-15, BD Pharmingem, San Jose, CA, USA),
MSH2 (Clone G219-1129, BD Pharmingem), MSH6
(Clone 44, BD Pharmingem) and PMS2 (Clone A16-4,
Zytomed Systems, Berlin, Germany) was performed
overnight at 4°C, at dilutions 1:100, 1:300, 1:1000, and
1:50 respectively, in 1% BSA in phosphate buffer saline
(PBS). All incubations were performed in a humified
chamber. Sections were developed with a peroxidase
substrate solution (0.05% 3,3-diaminobenzidine tetrahy-
drocloride, 0.01% H2O2 in PBS), counterstained with
hematoxylin, dehydrated and mounted. Appropriate
positive and negative controls were used for each anti-
body, i.e., internal controls (non-tumor tissue) and
external controls (cases with germline mutations at
MLH1, MSH2 and MSH6 genes). Assessment of MLH1,
MSH2, MSH6 and PMS2 immunoexpression was per-
formed by light microscopy at x400 magnification by a
pathologist (RH).
Screening for MSH2 and MSH6 germline alterations
Genomic DNA from two rectal cancer patients with
absent MSH2/MSH6 immunoreaction was screened for
MSH2 and MSH6 germline mutations. MSH2 and MSH6
coding exons (except MSH2 exons one and five and
MSH6 exon one and the acceptor splice site of exon 10)
were studied by Denaturing Gradient Gel Electrophoresis
(DGGE) using primers and conditions as described by
Wu et al [27] and Ingeny (The Netherlands). Fragments
with abnormal DGGE patterns and MSH2 exons one and
five and MSH6 exon one and the acceptor splice site
of exon 10 were analyzed by direct sequencing in an
ABI PRISM 310 automatic sequencer using Big Dye
Terminator Chemistry (Applied Biosystems), according
to the manufacturer’ s recommendations. Whenever
necessary, MSH6 exon seven was re-sequenced using
different set of primers to exclude or confirm the pre-
sence of a polymorphism at the initial primer annealing
site [28].
MSH2 and MSH6 exonic rearrangements were
screened by multiplex ligation-dependent probe amplifi-
cation (MLPA), according to the SALSA MLPA P003
MLH1/MSH2 Kit and P072MSH6 (MRC-Holland,
Amsterdam) instructions.
Statistical analysis
Statistical analysis was carried out with SPSS version 15.
Results were expressed in absolute frequencies and per-
centages. The statistical significance of no association
between different variables was performed with the
Fisher’ se x a c tt e s t .P values inferior to 0.05 were con-
sidered statistically significant.
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MSI target gene mutations and MLH1 methylation
Three of the 37 rectal and three of the 25 sigmoid carci-
nomas of the test series showed MSI-H [18]. Mutations
in the MSI target genes IGF2R and BAX were found in
one (33.3%) and two (66.7%) out of the three rectal
MSI-H carcinomas, respectively (Figure 1; Table 1),
whereas no mutations were detected in TGFBR2, MSH3,
and MSH6 microsatellite sequences in this test series.
None of the three MSI-H sigmoid carcinomas presented
mutations in any of the target genes analyzed. Further-
more, none of the six MSI-H rectal and sigmoid carci-
nomas presented MLH1 gene promoter methylation.
The histopathological features that characterize the
MSI-H tumors of the test series are presented in Table
1. No association was found between the presence of
MSI-H and clinicopathological features.
Intrigued by the low rate of target gene mutations and
absence of MLH1 hypermethylation in MSI-H rectal and
sigmoid carcinomas in the test series, we validated these
findings in an independent series of MSI-H carcinomas
arising from several locations of the large bowel
(Additional file 1, Table S1). After grouping the two
datasets we observed that the mutation frequency of the
target genes was associated with large bowel carcinoma
location (Table 2). TGFBR2 and MSH3 mutations were
detected more frequently in right MSI-H colon carcino-
mas (P = 0.00005 and P = 0.0000005, respectively) than
in MSI-H rectal and sigmoid carcinomas. IGF2R, BAX
and MSH6 mutations were also detected more fre-
quently in proximal colon carcinomas, but the difference
was not statistically significant (Table 2). Furthermore,
no MLH1 gene promoter hypermethylation was found
in any of the MSI-H rectal or sigmoid carcinomas of the
combined series, whereas it was found in 53% of carci-
nomas located elsewhere (P = 0.004).
KRAS and BRAF mutations
KRAS exon 2 mutations were detected in 13 (35.1%) of
the 37 rectal carcinomas of the test series (Additional
file 2, Table S2). All mutations occurred in codons 12
(69.2%) and 13 (30.8%) and the most frequent was
c.35G > A (Figure 2A). None of the cases with KRAS
mutations presented MSI-H, but two cases (15.4%)
Figure 1 Fragment analysis electrophorograms showing microsatellite sequences of BAT26 (A), IGF2R (G8) (B), BAX (G8) (C), and
TGFBR2 (A10) (D) in a rectal carcinoma (T41). Microsatellite instability was found in BAT26, IGF2R, BAX, but not in TGFBR2.
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sented mutations in KRAS exon 2, all in codons 12
(80%) and 13 (20%), and the most frequent was also
c.35G > A (Additional file 2, Table S2). One (20%) sig-
moid carcinoma with KRAS mutation presented MSI-H.
No mutations were detected in BRAF exon 15 in rectal
carcinomas of the test series, but one (4%) MSI-H sig-
moid carcinoma with no KRAS mutation presented the
mutation c.1799T > A (V600E) (Figure 2B).
When considering the MSI-H carcinomas of the com-
bined series, KRAS exon 2 mutations were detected in
five (19%) colon carcinomas located proximally to the
sigmoid and in four (25%) rectal/sigmoid carcinomas.
BRAF exon 15 mutations were detected in nine (43%)
proximal colon carcinomas and in two (17%) rectal/sig-
moid carcinomas. No statistically significant association
was found with tumor location (Table 2).
MMR immunohistochemistry and MSH2 /MSH6 germline
mutations
Of the six MSI-H carcinomas from the test series, none
of them presented criteria for MMR germline mutation
analysis, namely family history or early onset of cancer
(the average age of the patients with MSI-H carcinomas
was 68 years). However, sin c en o n eo ft h e mp r e s e n t e d
MLH1 promoter hypermethylation, MMR immunohisto-
chemical analysis was performed and two rectal carcino-
mas showed absence of MSH2/MSH6 expression (Table
1). One of these patients was shown to present a patho-
g e n i cg e r m l i n em u t a t i o ni nMSH2 exon 3 (Table 1).
MLH1 expression was normal in all MSI-H carcinomas
and PMS2 expression was normal in the four cases with
normal MLH1, MSH2 and MSH6 expression. As far as
can be ascertained from the information assessed from
written questionnaires, the patients of the validation ser-
ies did not fulfill the criteria for germline MMR muta-
tion analysis and therefore the MSI-H carcinomas were
considered sporadic [21].
Discussion
Existing data on MSI-H frequency indicate that it varies
from 10 to 20% in sporadic colorectal cancer, but varies
from less than 10% in sporadic rectal carcinomas to
about 40% in carcinomas from the right-sided colon
[10,17,18,29]. About 70% of MSI-H sporadic colorectal
cancers present MLH1 promoter hypermethylation [30].
Table 1 Histopathologic features, BAX and IGF2R microsatellite mutation status, BRAF mutation status, MMR protein
expression and mutation status in the rectal and sigmoid MSI-H carcinomas from the test series
Tumor
location
(sample
ID)
Morphology Differentiation Growth
pattern
Lymphocytic
infiltration
Mucinous BAX IGF2R KRAS BRAF MMR protein
expression
MMR
germline
mutation
Rectum
(T8)
Exophytic Moderate/well Expanding Moderate No Positive Negative Negative Negative MSH2/MSH6
absence
MSH2
c.388_389del
Rectum
(T20)
Ulcerated Moderate/well Expanding Moderate No Negative Negative Negative Negative Normal N.a.
Rectum
(T41)
Ulcerated/
exophytic
Moderate/well Expanding Moderate Yes Positive Positive Negative Negative MSH2/MSH6
absence
Negative
Sigmoid
(T27)
Ulcerated Well Infiltrating Sparse No Negative Negative Negative Negative Normal N.a.
Sigmoid
(T33)
Ulcerated/
exophytic
Moderate/well Expanding/
infiltrating
Sparse No Negative Negative Positive Negative Normal N.a.
Sigmoid
(T35)
Exophytic Poor Infiltrating Sparse No Negative Negative Negative Positive Normal N.a.
MMR - Mismatch repair. MSI-H - microsatellite instability-high. T- test series; N.a. - not analyzed; TGFBR2, MSH3 and MSH6 mutations and MLH1 methylation were
not found.
Table 2 TGFBR2, BAX, IGF2R, MSH3, MSH6 microsatellite sequences, BRAF and KRAS mutation frequency and MLH1
promoter hypermethylation status in the MSI-H colorectal cancer according to the large bowel of origin (rectal/
sigmoid carcinomas compared with those located elsewhere in the colon from both series)
Tumor location TGFBR2
(%)
BAX
(%)
IGF2R
(%)
MSH3
(%)
MSH6
(%)
MLH1 methylation
(%)
KRAS
(%)
BRAF
(%)
Proximal Colon 23/26 (88) 12/26 (46) 8/26 (31) 20/26 (77) 5/26 (19) 10/19 (53) 5/26 (19) 9/21 (43)
Rectum/Sigmoid 4/16 (25) 3/16 (19) 3/16 (19) 0/16 (0) 1/16 (6) 0/12 (0) 4/16 (25) 2/12 (17)
P = 0.00005 P = 0.102 P = 0.485 P = 0.0000005 P = 0.380 P = 0.004 P = 0.711 P = 0.249
MSI-H - microsatellite instability-high.
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regions D (in the test series) and C (in the MSI-H vali-
dation series), which are both strongly associated with
MLH1 protein expression [31]. None of the rectal and
sigmoid MSI-H carcinomas of both series presented
MLH1 promoter hypermethylation, which we confirmed
is significantly associated with colon tumors located
more proximally (P = 0.004). These data are compatible
with the recent observation of Watanabe et al [32] that
MLH1 promoter methylation is significantly less com-
m o ni nl e f tt h a ni nr i g h tM S I - Hc o l o r e c t a lc a n c e r .T h i s
difference is reflected in distinct gene expression pro-
files, which could be taken to indicate that left MSI-H
colorectal cancer is a pathogenetically different sub-
group among MSI-H sporadic carcinomas [32].
Genes with repetitive sequences located in coding
regions are prone to mutations in colorectal carcinomas
with the MSI-H phenotype. In fact, there is a well estab-
lished association between an ineffective MMR system
and mutations in the target genes that we have studied,
which presumably play a relevant role in colorectal car-
cinogenesis through the MSI pathway [9,33]. In rectal
MSI-H carcinomas of the test series, we detected muta-
tions only in IGF2R and BAX genes, possible indicating
that they are also target genes in the MSI pathway in
rectal cancer. The TGFBR2 coding (A)10 sequence is
among the most frequently mutated (70 to 90%) sites in
MSI-H colorectal carcinomas, indicating that alterations
in this gene are crucial for the development of MSI neo-
plasias [9,34]. Furthermore, the mutational frequency in
MSI-H colorectal cancer is 20 to 39% for MSH3 and 30
to 40% for MSH6 [33,35]. Interestingly, we did not
detect any mutation in TGFBR2, MSH3,o rMSH6
microsatellite sequences in rectal or sigmoid MSI-H car-
cinomas in our test series. In order to confirm these
findings, we compared our data with those of an inde-
pendent series of MSI-H carcinomas with origin in each
of the large bowel regions. The trend observed in the
test series was confirmed in the validation set, and when
all MSI-H carcinomas of the two series are grouped
together we observed that TGFBR2 and MSH3 muta-
tions were significantly more prevalent in proximal than
in distal (sigmoid and rectal) cancers (P = 0.00005 and
P = 0.0000005, respectively). This disparity suggests that
these genes are not commonly involved in the develop-
ment of rectal and sigmoid cancer through the MSI
pathway or that alternative mechanisms of inactivation
exist. Qualitative (type of target gene) and quantitative
Figure 2 Sequence electrophorograms showing KRAS and BRAF mutations. A- Rectal carcinoma presenting the mutation c.35G > A (arrow)
in KRAS exon 2 to the left and the normal tissue sample to the right (sequencing analysis is in the reverse direction); B- Sigmoid carcinoma
presenting the mutation c.1799T > A (V600E) (arrow) in BRAF exon 15 to the left and the corresponding normal tissue sample to the right.
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ences have been observed regarding MSI-H target genes
in different types of cancers. For instance, TGFBR2
mutational frequency is higher in MSI-H colon carcino-
mas (70 to 90%) than in MSI-H endometrium carci-
noma (17 to 19%), suggesting that biological features
and functional roles of target genes may differ depend-
ing on the tissue of tumor origin [33,34]. Our data sug-
gest that both the mechanism of MSI-H and its target
genes differ in colorectal carcinomas depending on large
bowel site of origin.
Based on clinical data, germline mutations in the mis-
match repair genes were initially considered unlikely.
H o w e v e r ,s i n c en o n eo ft h eM S I - Hr e c t a la n ds i g m o i d
carcinomas presented MLH1 promoter methylation, we
performed immunohistochemical staining to determine
the expression of the MMR proteins MLH1, MSH2,
MSH6 and PMS2. Two MSI-H rectal carcinomas
showed absence of MSH2/MSH6 proteins and subse-
quent mutation analysis demonstrated that one of the
patients presented a germline mutation in MSH2 exon
3. We did not detect any mutation either in the MSH2
or MSH6 genes in the second patient, although it may
exist in the promoter or intronic regions not probed in
this investigation. These two cases presented also altera-
tions in the BAX and IGF2R genes in their carcinomas
(Table 1), which are compatible with a constitutional
MMR deficiency that leads to an acquired genetic
instability. The immunohistochemical expression of all
four MMR proteins in the remaining four cases does
not necessarily imply normal DNA mismatch repair
function, as missense mutations in MSH2, MLH1 or
MSH6 genes may give rise to normal protein levels but
abnormal function [36]. Although we did not perform
MMR mutation analysis in the validation series, the
patient age composition as a whole does not fit a Lynch
syndrome profile, as the mean age in the validation ser-
ies is 68 years, with only three cases unmethylated at
the MLH1 promoter being of young age (33-41 years
old), all rectal or sigmoid. Additionally, de novo germ-
line mutations in other MMR components cannot be
ruled out for neither the test (one rectal and the three
sigmoid MSI-H tumors with normal MLH1, MSH2,
MSH6, and PMS2 immunohistochemical staining) nor
the validation series. As mentioned above, TGFBR2,
MSH3 and MSH6 microsatellite sequences present high
mutational rates in right MSI-H colorectal cancer,
demonstrating that alterations in these genes are impor-
tant for the development of MSI neoplasias [9,34]. The
fact that we detected significantly less mutations in
these three genes in distal MSI-H carcinomas, even in a
rectal carcinoma arising in an individual with a MMR
constitutional deficiency, could indicate that these genes
are not essential for the cancer development in the sig-
moid and rectum. It would be interesting to examine
for location differences of other genes showing a high
mutation frequency in MSI-H tumors such as AC1,
ACVR2A, HT001, MRE11A, PTHLH,a n dTAF1B,w h i c h
all carry mononucleotide repeats in the coding region
and show a mutation frequency of ~70% or higher.
However, the relevance of these genes in rectal tumori-
genesis remains to be clarified [35].
Several studies have demonstrated the relevance of
the MAPK signaling pathway in colorectal cancer, par-
ticularly involving alterations in the proto-oncogenes
KRAS and BRAF. Deregulation of this pathway can
result in apoptosis inhibition and uncontrolled cell
proliferation [11-14]. When considering the MSI-H
carcinomas of the combined series, BRAF exon 15
mutations were detected in 17% of the rectal/sigmoid
carcinomas and in 43% of those located elsewhere in
the colon. Although no statistically significant associa-
tion was found with tumor location (P = 0.249), BRAF
mutations were observed more frequently in proximal
than in distal carcinomas, which is in agreement with
previous studies reporting that BRAF mutations occur
more frequently in carcinomas arising in the right
colon (17.8% versus 3.6% in rectal carcinomas) [13,17].
Several articles found an association between BRAF
mutations (namely V600E) and the MSI-H phenotype
caused by MLH1 gene promoter hypermethylation (fre-
quently in the right colon), but the sigmoid and rectal
carcinoma in our test and validation series, respec-
tively, with BRAF mutation were MSI-H and did not
present MLH1 promoter hypermethylation [37,38]. On
the other hand, when considering the total series of
MSI-H carcinomas, KRAS mutation frequency was
similar for proximal (19%) and distal (25%) carcinomas
and inferior to the one observed in microsatellite
stable tumors, as previously described [13,14,24].
These findings demonstrate that the MAPK pathway
involvement in rectal and sigmoid cancer occurs pre-
ferentially by KRAS activation.
Conclusions
Our findings in two independent series from different
countries indicate that the pattern of genetic changes
involved in rectal and sigmoid carcinogenesis is partially
different from that observed elsewhere in the colon. As
the mutational spectrum of the MSI pathway appears to
differ, the carcinogenic mechanisms may also be distinct
between MSI-H carcinomas of the recto-sigmoid and
those localized more proximally. Further investigation is
warranted to determine the mechanism of MSI-H and
its target genes in distal colorectal carcinogenesis both
in patients with sporadic or hereditary disease.
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Additional file 1: Clinical and genetic parameters evaluated in the
MSI-H tumors according to the large bowel site of origin. Table
presenting the clinical and genetic parameters evaluated in the MSI-H
tumors enrolled in this study.
Additional file 2: Somatic mutations detected in KRAS exon 2 in
rectal and sigmoid cancer patients from the test series. Table
showing the somatic mutations detected in KRAS exon 2 in rectal and
sigmoid cancer patients from the test series.
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